Contract Development Services

The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.

Contract testing services demonstrate a major increase in the speed and efficiency of testing using new testing methods and technologies.

Quotient Sciences’ facility expansion is designed to increase support for fully integrated drug development programs.

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

In the coming year, pharmaceutical innovation will be fueled by key trends throughout the quality sector.

The COVID-19 pandemic has led to many changes and shifts in the pharmaceutical industry, specifically with how pharmaceutical companies develop vaccines.

The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.

The CPHI Annual Report 2022 predicts cash reserves from venture capitalists and private equities will drive expansion in the demand for contract research organizations and contract development and research organizations.

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Sponsors should explore key considerations ahead of choosing a new outsourcing partner.

External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.

Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.

The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally.

The inaugural Connect in Pharma event will take place on 14 and 15 September in Geneva, Switzerland.

Partnering with an experienced service provider can help companies unlock the commercial potential of new therapeutic approaches.

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.

Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource.

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

CDMOs offer expertise and customization options for sponsors of orphan drugs.

Sterling Pharma Solutions has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, UK.

Investing in formulation strategies earlier on in development will maximize the chance of success.

Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.

Collaborative partnerships can foster success in formulation development projects.

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.